FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4235685751> ?p ?o ?g. }

• W4235685751 endingPage "103" @default.
• W4235685751 startingPage "103.2" @default.
• W4235685751 abstract "<h3>Background</h3> T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent studies highlight a surprising role for T-cell derived granulocyte-macrophage colony stimulating factor (GM-CSF) in the pathogenicity of Th17 cells. <h3>Objectives</h3> We examined the mechanism by which interleukin 17 (IL-17) and GM-CSF contribute to cartilage- and bone damage of synovial joints during experimental arthritis, and investigated their potential additive and synergistic effects to provide a rationale for combination therapy in auto-inflammatory conditions. <h3>Methods</h3> Collagen-induced arthritis (CIA) was elicited in DBA/1J mice. Neutralizing antibodies to IL-17 and/or GM-CSF were administered after onset of disease for 14 days. Arthritis progression was followed by macroscopic scoring of the paws (maximum score of 12 per mouse). In addition, the effect of local over-expression of IL-17 and/or GM-CSF was studied by adenoviral transfection in naïve knee joints. Joint pathology was studied by X-ray and histology, and Luminex and QPCR were performed to determine cytokine en chemokine expression. <h3>Results</h3> Combined therapeutic treatment of mice early after the onset of CIA ameliorated disease progression. Macroscopic joint inflammation was significantly reduced, from a total score of 5.6±0.4 for mice treated with isotype control antibodies to 2±0.6 for mice treated with combination therapy. Treatment with anti-IL-17 or anti-GM-CSF alone resulted in scores of 3.4±0.5 and 3.5±0.4, respectively. Simultaneous blocking of GM-CSF and IL-17 was also the most effective treatment in the prevention of radiological bone damage and histological cartilage destruction. To provide further insight in local additive or synergistic effects of IL-17 and GM-CSF, overexpression of IL-17, GM-CSF or the combination was achieved with adenoviral vectors. Inflammatory infiltrate and cartilage- and bone damage developed in all groups from day 1 after adenoviral transfer, with the most severe effect observed in the combination group. On day 7, partial destruction of joint architecture was apparent in knee joints after combined overexpression of IL-17 and GM-CSF. Overexpression of GM-CSF alone induced IL-1β, which production was elevated by IL-17. Interestingly, overexpression of IL-17 alone caused a clear increase in synovial IL-6 production (179±63 pg/ml), which was dramatically enhanced in the co-presence of GM-CSF (1,9±0,4 ng/ml). In addition, a strong synergistic effect of combined overexpression was seen on the Th17 differentiation factor IL-23. <h3>Conclusions</h3> Our results demonstrate that the combined presence of IL-17 and GM-CSF causes aggravated joint damage through synergistic effects on inflammatory mediators in the synovial joints. In view of the moderate success of therapeutic IL-17 or GM-CSF blockade in rheumatoid arthritis, combined inhibition of IL-17 and GM-CSF might be an interesting alternative option for RA patients that do not fully respond to inhibition of the separate cytokines. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5430" @default.
• W4235685751 created "2022-05-12" @default.
• W4235685751 creator A5023004311 @default.
• W4235685751 creator A5026099590 @default.
• W4235685751 creator A5032135051 @default.
• W4235685751 creator A5043177337 @default.
• W4235685751 creator A5045199963 @default.
• W4235685751 creator A5045215696 @default.
• W4235685751 creator A5048891671 @default.
• W4235685751 creator A5053412830 @default.
• W4235685751 creator A5074893682 @default.
• W4235685751 date "2014-06-01" @default.
• W4235685751 modified "2023-10-14" @default.
• W4235685751 title "OP0112 Synergism between GM-CSF and IL-17 Causes Enhanced Joint Pathology via the Production of IL-6 and IL-23" @default.
• W4235685751 doi "https://doi.org/10.1136/annrheumdis-2014-eular.5430" @default.
• W4235685751 hasPublicationYear "2014" @default.
• W4235685751 type Work @default.
• W4235685751 citedByCount "2" @default.
• W4235685751 countsByYear W42356857512017 @default.
• W4235685751 countsByYear W42356857512023 @default.
• W4235685751 crossrefType "journal-article" @default.
• W4235685751 hasAuthorship W4235685751A5023004311 @default.
• W4235685751 hasAuthorship W4235685751A5026099590 @default.
• W4235685751 hasAuthorship W4235685751A5032135051 @default.
• W4235685751 hasAuthorship W4235685751A5043177337 @default.
• W4235685751 hasAuthorship W4235685751A5045199963 @default.
• W4235685751 hasAuthorship W4235685751A5045215696 @default.
• W4235685751 hasAuthorship W4235685751A5048891671 @default.
• W4235685751 hasAuthorship W4235685751A5053412830 @default.
• W4235685751 hasAuthorship W4235685751A5074893682 @default.
• W4235685751 hasConcept C105702510 @default.
• W4235685751 hasConcept C13373296 @default.
• W4235685751 hasConcept C142724271 @default.
• W4235685751 hasConcept C159654299 @default.
• W4235685751 hasConcept C203014093 @default.
• W4235685751 hasConcept C2776914184 @default.
• W4235685751 hasConcept C2777077863 @default.
• W4235685751 hasConcept C2777478134 @default.
• W4235685751 hasConcept C2778690821 @default.
• W4235685751 hasConcept C2780130043 @default.
• W4235685751 hasConcept C2780550940 @default.
• W4235685751 hasConcept C47348012 @default.
• W4235685751 hasConcept C71924100 @default.
• W4235685751 hasConceptScore W4235685751C105702510 @default.
• W4235685751 hasConceptScore W4235685751C13373296 @default.
• W4235685751 hasConceptScore W4235685751C142724271 @default.
• W4235685751 hasConceptScore W4235685751C159654299 @default.
• W4235685751 hasConceptScore W4235685751C203014093 @default.
• W4235685751 hasConceptScore W4235685751C2776914184 @default.
• W4235685751 hasConceptScore W4235685751C2777077863 @default.
• W4235685751 hasConceptScore W4235685751C2777478134 @default.
• W4235685751 hasConceptScore W4235685751C2778690821 @default.
• W4235685751 hasConceptScore W4235685751C2780130043 @default.
• W4235685751 hasConceptScore W4235685751C2780550940 @default.
• W4235685751 hasConceptScore W4235685751C47348012 @default.
• W4235685751 hasConceptScore W4235685751C71924100 @default.
• W4235685751 hasIssue "Suppl 2" @default.
• W4235685751 hasLocation W42356857511 @default.
• W4235685751 hasOpenAccess W4235685751 @default.
• W4235685751 hasPrimaryLocation W42356857511 @default.
• W4235685751 hasRelatedWork W1994888681 @default.
• W4235685751 hasRelatedWork W2013060765 @default.
• W4235685751 hasRelatedWork W2070463916 @default.
• W4235685751 hasRelatedWork W2073921819 @default.
• W4235685751 hasRelatedWork W2105678915 @default.
• W4235685751 hasRelatedWork W2126005292 @default.
• W4235685751 hasRelatedWork W2146036781 @default.
• W4235685751 hasRelatedWork W2168641931 @default.
• W4235685751 hasRelatedWork W2313033156 @default.
• W4235685751 hasRelatedWork W41833562 @default.
• W4235685751 hasVolume "73" @default.
• W4235685751 isParatext "false" @default.
• W4235685751 isRetracted "false" @default.
• W4235685751 workType "article" @default.